SEC Form 4 · accession 0001140361-17-047821
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
CPMG Inc
Director · 10% Owner
Period of report
Dec 29, 2017
Accepted (ET)
Dec 29, 2017 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF1,F2 | Dec 29, 2017 | P | 17,000 | $28.4715 | A | 44,200 | I | By Barred Owl Partners, LP |
| Class A common stockF2 | holding | — | — | — | 34,897 | I | By Managed Account for Trustees of the University of Pennsylvania | |
| Class A common stockF2 | holding | — | — | — | 442,560 | I | By Gallopavo, LP | |
| Class A common stockF2 | holding | — | — | — | 748,253 | I | By Roadrunner Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 103,185 | I | By Blackwell Partners LLC | |
| Class A common stockF2 | holding | — | — | — | 431,155 | I | By Yellow Warbler, LP | |
| Class A common stockF2 | holding | — | — | — | 110,640 | I | By Killdeer Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 109,415 | I | By Mallard Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 280,500 | I | By Willet Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 37,909 | I | By Crested Crane, LP | |
| Class A common stockF2 | holding | — | — | — | 63,481 | I | By Flamingo Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 334,740 | I | By Sandpiper Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 160,265 | I | By Kestrel Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 11,076 | I | By CD Fund, LP | |
| Class A common stockF2 | holding | — | — | — | 134 | I | By Redbird Life Sciences Partners, LP | |
| Class A common stock | holding | — | — | — | 113 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This price reflects the weighted average purchase price for open-market purchases on December 29, 2017, within a $1.00 range. The actual prices for these transactions range from $28.40 to $28.50 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
- F2The Reporting Person is the investment manager of each of: Barred Owl Partners, LP; Killdeer Fund, LP; Blackwell Partners LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; Redbird Life Sciences Partners, LP.; and a managed account for Trustees of the University of Pennsylvania. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Remarks
Mr. McGaughy, Jr., a co-director and co-shareholder of the Reporting Person, serves on the Issuer's Board of Directors (the "Board") as a representative of the Reporting Person. By virtue of his representation on the Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person is deemed to be a director by deputization.